• Mashup Score: 7
    Optimising adjuvant treatment in HR+/HER2-neg early breast cancer - 3 year(s) ago

    Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOBreast22: Gene-expression assays have produced a huge step forward in optimising adjuvant treatment in HR+/HER2- early #BreastCancer after surgery, but there is still a long way to go in the more specific targeting of treatment 👉 https://t.co/ZyNglFgumk @jsparano https://t.co/9oIn8T8BGF

  • Mashup Score: 0
    Fred R. Hirsch receives the Heine H. Hansen Award 2022 - 3 year(s) ago

    In his Keynote Lecture at the European Lung Cancer Congress 2022, Prof. Fred R. Hirsch describes how ‘the tissue is still the issue’

    Source: Daily Reporter
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of jsparano
      jsparano

      https://t.co/xFCynYgAxT Congratulations to Fred Hirsch @MountSinaiNYC for being the recipient of the 2022 ESMO Heine H. Hansen Award for his contributions to lung cancer research.

  • Mashup Score: 0
    PROs are essential when promptly available - 3 year(s) ago

    Patient-reported outcomes are not generally published alongside primary efficacy and safety data

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC22: In his editorial, @MassimoDiMaio75 stresses that PROs results provide important information for treatment decisions and should be published alongside the efficacy and safety data 👉https://t.co/sixECgN9Yv https://t.co/JbN0Up3Pa8

  • Mashup Score: 1
    How long should we give immunotherapy for? - 3 year(s) ago

    Definitive studies investigating the optimum duration against the risk-benefit profile of immunotherapy for metastatic lung cancer are still lacking

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC22: How long should we give immunotherapy? For metastatic #LungCancer, the course length was arbitrarily set at 2 years in #ClinicalTrials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking. 👉https://t.co/Q9Ks7cRuuK https://t.co/e70unzbwAo

  • Mashup Score: 6
    Durvalumab after sequential chemotherapy unresectable NSCLC - 3 year(s) ago

    Safety data from the PACIFIC-6 trial are encouraging and represent a potential alternative for vulnerable and older patients

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC22: Findings from the PACIFIC-6 trial show that the safety profile of durvalumab treatment who had not progressed after sCRT was similar to that observed after concurrent chemoradiotherapy (cCRT) in stage III unresectable #NSCLC 👉 https://t.co/cHwYuZWiBZ @DrJNaidoo https://t.co/egOh9wzvGI

  • Mashup Score: 10
    Durvalumab after sequential chemotherapy unresectable NSCLC - 3 year(s) ago

    Safety data from the PACIFIC-6 trial are encouraging and represent a potential alternative for vulnerable and older patients

    Source: Daily Reporter
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of DrJNaidoo
      DrJNaidoo

      #ELCC22 PACIFIC-6: Durva after seq chemoRT in stage III nsclc @marinagarassino: - 117 pts - 4.3% G3+ TRAEs in first 6m - 10.3% Tx discontd from pneumonitis 🎤thanks @myESMO for inviting me to provide a daily reporter commentary here: https://t.co/PrRZpbGCS9 @CancerCentreIre https://t.co/smBF08r4k7

  • Mashup Score: 4
    Results for two new third-generation EGFR TKIs - 3 year(s) ago

    Investigated among Asian populations, they do not suggest advantages over osimertiib for first-line treatment of EGFR-mutated NSCLC

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ELCC22: In two studies presented, the third-generation #EGFR TKIs furmonertinib and oritinib do not suggestan advantage over osimertinib in Asian patients with EGFR-mutated NSCLC 👉https://t.co/EUrurkTYxG @BenjaminBesseMD https://t.co/F30jrvoJ4U

Load More